Analyzing Arcellx (NASDAQ:ACLX) and Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Aardvark Therapeutics and Arcellx”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$20.59 million	($2.12)	-2.48
Arcellx	$22.29 million	299.85	-$228.93 million	($4.07)	-28.08

Aardvark Therapeutics has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aardvark Therapeutics and Arcellx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-54.90%	-37.86%
Arcellx	-1,027.26%	-55.42%	-36.24%

Insider & Institutional Ownership

96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Aardvark Therapeutics and Arcellx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	1	4	7	1	2.62
Arcellx	1	17	1	0	2.00

Aardvark Therapeutics presently has a consensus target price of $25.09, suggesting a potential upside of 377.01%. Arcellx has a consensus target price of $111.87, suggesting a potential downside of 2.12%. Given Aardvark Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Arcellx.

Summary

Aardvark Therapeutics beats Arcellx on 9 of the 13 factors compared between the two stocks.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

About Arcellx

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.